Toxicological Risk Assessment Replacing Animal Tests
How the medical device industry is moving toward more ethical, scientific, and efficient approaches to biocompatibility evaluation.
The medical device industry is moving toward more ethical, scientific and efficient approaches to biocompatibility evaluation. One of the most significant developments in recent years is the increasing use of Toxicological Risk Assessment (TRA) to replace or reduce animal testing. Regulatory authorities now encourage methods that protect patient safety while minimizing the use of animals.
Under ISO 10993-17, toxicological risk assessment provides a structured framework to evaluate patient exposure to chemicals released from medical devices. With ISO 10993-1:2025, TRA has become a central element of biocompatibility assessment. In this blog, Accuprec Research Labs Pvt. Ltd. explains how toxicological risk assessment is replacing animal tests and why this approach is gaining regulatory acceptance.
Toxicological Risk Assessment is a scientific process used to evaluate whether chemical substances released from a medical device pose a risk to patients. Instead of relying on animal testing, TRA uses:
- Chemical characterization data
- Exposure assessment
- Toxicological thresholds
- Scientific literature
This approach allows manufacturers to assess safety in a human-relevant and ethical manner.
ISO 10993-17 provides guidance on establishing allowable limits for substances released from medical devices. It focuses on:
- Identification of chemicals
- Estimation of patient exposure
- Comparison with tolerable intake values
ISO 10993-17 works together with ISO 10993-18 and ISO 10993-1 to support risk-based evaluation.
Animal testing has several limitations, including:
- Ethical concerns
- High cost and long timelines
- Limited relevance to human exposure
- Variability in results
Regulatory authorities now prefer alternative methods that are more predictive of human risk.
Chemical Identification and Quantification
TRA begins with chemical characterization studies to identify extractables and leachables. Analytical techniques help quantify substances that may be released during device use. This step replaces exploratory animal testing by focusing on actual chemical exposure.
Patient Exposure Assessment
Exposure is calculated based on: Device contact type, Duration of use, and Frequency of exposure. This provides a realistic estimate of what patients are exposed to, unlike worst-case animal tests.
Toxicological Evaluation
Each identified chemical is evaluated using: Published toxicological data, Regulatory databases, and Acceptable intake limits. This allows risk assessment without animal testing.
Margin of Safety Determination
By comparing exposure levels with safe thresholds, a margin of safety is established. If the margin is acceptable, additional animal testing may not be required.
Toxicological risk assessment offers several advantages:
- Reduced use of animals
- Faster evaluation timelines
- Lower development costs
- Human-relevant safety assessment
- Strong regulatory acceptance
These benefits make TRA a preferred approach under ISO 10993-1:2025.
FDA Perspective: The FDA supports TRA as a scientifically justified alternative to animal testing when supported by adequate data. Submissions using TRA often face fewer regulatory questions.
EU MDR Perspective: EU Notified Bodies increasingly accept TRA, especially when combined with chemical characterization and strong documentation.
Although TRA is powerful, animal testing may still be required when:
- Chemical data is insufficient
- Exposure cannot be reliably estimated
- Novel materials lack toxicological information
In such cases, animal testing must be scientifically justified.
Manufacturers may face challenges such as: Incomplete chemical data, Complex exposure scenarios, or Limited toxicological information for certain substances. To maximize regulatory acceptance, manufacturers should:
- Perform robust chemical characterization
- Use conservative but realistic exposure assumptions
- Reference reliable toxicological data sources
- Clearly document assumptions and conclusions
Transparency and scientific rigor are essential. Expert toxicological support helps overcome these challenges.
Accuprec Research Labs Pvt. Ltd. provides comprehensive support for toxicological risk assessment, including:
- ISO 10993-17–compliant TRA
- Chemical characterization studies
- Exposure assessment
- Regulatory-ready documentation
Our expertise helps reduce animal testing while maintaining patient safety.
Toxicological Risk Assessment is transforming biocompatibility evaluation by providing a scientific, ethical and regulator-accepted alternative to animal testing. Under ISO 10993-1:2025 and ISO 10993-17, TRA plays a central role in modern medical device development.
Manufacturers who adopt TRA can improve approval timelines, reduce costs and align with global regulatory expectations.
